T1	Participants 381 488	patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy
T2	Participants 713 730	patients with MDS
T3	Participants 1007 1056	patients with neutrophil counts of >0.1 x 10(9)/L
T4	Participants 1301 1351	patients with AML or MDS who received chemotherapy
